Salt Lake City, October 21st / PRNewswire / -- Sera Prognostics Inc. ( The Pregnancy Company ®, NASDAQ ticker: SERA ) announced today that it will release its financial results for the third quarter of fiscal year 2026 after the close of U.S. markets on Wednesday, November 4, 2026. The company will also hold a corresponding conference call and webcast at 5:00 p.m. Eastern Time to discuss operational highlights, financial results, and key matters. The company will pre-release a press release explaining the financial results and highlights before the conference call.

Call details:

• To call within the United States: 800-836-8184
• International call: 646-357-8785
• Online live streaming registration link: https :// app.webinar.net / wK8exGQrE0B

The audio from the live webcast will be available for listening on the investors' page of the company's website at www.sera.com. This live webcast will also be archived on the investors' page and can be watched for a period of one year.

Regarding Sera Prognostics, Inc.

Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and infants through precision pregnancy care. The company's mission is to provide early and critical pregnancy information to enhance the health of mothers and newborns, as well as to reduce healthcare costs. Sera boasts a robust pipeline of innovative diagnostic tests that focus on early prediction of premature birth risk and other pregnancy complications. The company's precision medicine PreTRM ® Test can report to doctors the individualized risk of spontaneous premature birth in pregnant women, enabling high-risk women to receive proactive intervention at an earlier stage. Sera Prognostics is headquartered in Salt Lake City, Utah.

About Premature Birth

Premature birth refers to any delivery before 37 weeks of gestation and is a major cause of illness and death in newborns. March of Dimes The 2025 report card shows that the United States received a D+ rating for premature birth for the fourth consecutive year, which is also the longest duration of this lowest rating in the history of such reports. Premature birth is significantly associated with an increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory diseases, intellectual disabilities, epilepsy, as well as vision and hearing loss, and can incur considerable costs throughout the affected children's lives. The annual medical costs incurred by the United States to manage the short-term and long-term complications of premature birth were estimated at approximately 25 billion dollars in 2016.

Regarding PreTRM ® Test

PreTRM ® Test is the only widely validated, commercially available test based on blood biomarkers that can provide early, accurate, and personalized predictions of the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. This test helps doctors identify which women are at higher risk of preterm birth and its complications between weeks 18 and 20 of pregnancy by measuring and analyzing proteins in the blood that are highly predictive of preterm birth, thereby allowing for more informed and personalized clinical decisions based on each woman's individual risk. PreTRM ® Test must be prescribed by a medical professional.

Sera, Sera Prognostics, Sera Prognostics, The Pregnancy Company, and PreTRM are all Sera Prognostics, Inc. They are trademarks or registered trademarks in the United States and/or other countries.

Safe Harbor Statement

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, including statements regarding the dates, times, and contents of the company’s quarterly earnings press releases and conference calls; statements from the live audio of the conference calls that can be listened to on the company’s website; and the company’s strategic guidance described in the section titled “Regarding Sera Prognostics, Inc.” These forward-looking statements are based on management’s current expectations of future events and are subject to various risks and uncertainties that may result in material differences between actual results and those stated or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation capabilities, and the potential need to raise additional capital; as of now, revenue from PreTRM Test constitutes the majority of the company’s revenue; PreTRM Test requires widespread scientific and market recognition; a concentration of significant customers; the company’s ability to launch new products; potential competition; the company’s proprietary bio-sample bank; key suppliers; estimates of the total addressable market opportunities and market growth forecasts; potential third-party payer coverage and reimbursement; new reimbursement methods applicable to PreTRM Test, including the new CPT codes and their payment rates; changes in regulations for laboratory-developed tests by FDA; intellectual property that protects the company’s testing and market position; and other factors discussed under the “Risk Factors” section in the company’s annual 10-K and quarterly 10-Q reports filed with the U.S. Securities and Exchange Commission, as well as updates to these risk factors in the periodic and regulatory reports submitted from time to time. Except as required by law, the company has no obligation to update the information in this press release. All information in this press release is valid as of the date of issuance.

Investor Contact

Jennifer Zibuda, Head of Investor Relations